# US 2026/0098049 A1 · Kras modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098049 A1
- Document ID: US20260098049A1
- Status: Published application
- Kind: A1
- Application number: 19/296,626
- Filed: 2025-08-11
- Published: 2026-04-09
- Earliest claimed: 2024-08-12
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Eda Y. Canales; Christopher T. Clark; Zhimin Du; Yassin M.A. Elbatrawi; Quinn B. Greven; Tezcan Guney; Darryl Kato; Henok H. Kinfe; Irene N. Kiburu; Scott E. Lazerwith; Thomas C.J. Mies; Christopher J. Swank; Rhiannon Thomas-Tran; Guanghu Tong; William J. Watkins; Wilian Augusto Cortopassi Coelho
- Web page: https://patentgrep.com/patent/US20260098049A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
each RC1 is independently H, C1-C6 alkyl, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, —CN, C1-C6 cyanoalkyl, C3-C6 cycloalkyl, ═CH2, ═CHF, or ═CF2, or
alternatively, two RC1 attached to the same carbon form a C3-C6-membered cycloalkyl or 4- to 6-membered heterocyclyl, wherein the cycloalkyl and heterocyclyl is substituted by 0, 1, or 2 halo;
Z1 is —(CR2fR2g)m—;
R2f and R2g are each independently H, C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, —CN, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R2f f and R2g can combine with the carbon to which they are attached to form a C3-C6 cycloalkyl;
m is 1, 2, or 3;
ring C2 is 4- to 16-membered heterocyclyl having at least one ring nitrogen;
each RC2 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6 thiohaloalkyl, —OH, oxo, —CN, C1-C6 cyanoalkyl, or C3-C6-cycloalkyl;
n is 0, 1, 2, 3, or 4;
Z2 is C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C4 cycloalkyl, —O—C1-C3 alkyl, —O—C2-C3 alkenyl, —O—C2-C3 alkynyl, —O—, —S—, —NRZ2b—, —C(O)—, —S(O)—, S(O)2—, S(O)(═NRZ2)—, oxetanyl, or a bond; wherein the alkyl and cycloalkyl is substituted with 0, 1, 2, 3, or 4 Z2a; wherein the alkenyl is substituted with 0, 1, or 2 Z2c;
each Z2a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6thiohaloalkyl, —OH, —CN, C1-C6 cyanoalkyl, C3-C6 cycloalkyl, or 4- to 10-membered heterocyclyl;
each Z2c is independently C1-C6 alkyl, halo, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
RZ2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
RZ2b is H, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
ring C3 is C3-C8 cycloalkyl, 4- to 16-membered heterocyclyl, C6-C10 aryl, 5- to 10-membered heteroaryl, or absent;
each RC3 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6 thiohaloalkyl, —OH, oxo, —CN, C1-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, C1-C6 cyanoalkyl, or C3-C6-cycloalkyl;
p is 0, 1, 2, 3, or 4;
Z5 is C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C3-C4 cycloalkyl, —O—C1-C3 alkyl, —O—C2-C3 alkenyl, —O—C2-C3 alkynyl, —O—, —S—, —NRZ5b—, —C(O)—, —S(O)—, S(O)2—, S(O)(═NRZ5)—, or a bond; wherein the alkyl and cycloalkyl is substituted with 0, 1, 2, 3, or 4 Z5a;
each Z5a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6thiohaloalkyl, —OH, —CN, C1-C6 cyanoalkyl, C3-C6 cycloalkyl, or 4- to 10-membered heterocyclyl;
RZ5 is H, C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl;
RZ5b is H, C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl;
ring C4 is 5 to 14-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
each RC4 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6 thiohaloalkyl, —OH, oxo, —CN, C1-C3 cyanoalkyl, C3-C6 cycloalkyl, or 4- to 10-membered heterocyclyl;
q is 0, 1, 2, 3, or 4;
Z3 is —NH—, —C(O)NH—, or a bond, and Z4 is —CH—;
alternatively, Z3 is a bond and Z4 is N;
X is N, CH, or CRx;
Rx is halo, C1-C3 haloalkyl, or C1-C3 cyanoalkyl;
L1 is O, CR1aR1b, C(═CR1cR1d), C(═O), or —C(R1e)═;
R1a and R1b are each independently H, C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, —CN, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R1a and R1b can combine with the atom to which they are attached to form a C3-C6 cycloalkyl or a 3 to 6-membered heterocyclyl having 1 heteroatom that is O, wherein each cycloalkyl and heterocyclyl is substituted with 0, 1, 2, or 3 R1x;
R1c and R1d are each independently H, C1-C3 alkyl, halo, or C1-C6 haloalkyl;
R1e is H, C1-C3 alkyl, halo, C1-C6 haloalkyl, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
each R1x is independently C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, or —OH;
L2 is a bond or CR2aR2b, C(═CR2cR2d), C(═O), ═C(R2e)—, O, or S, such that when L2 is O or S, then L1 is CR1aR1b;
R2a and R2b are each independently H, C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, —CN, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R2a and R2b can combine with the atom to which they are attached to form a C3-C6 cycloalkyl;
alternatively, R1b and R2b can combine with the atoms to which they are attached to form a C3-C6 cycloalkyl, 4- to 10-membered heterocyclyl, C6-C10 aryl, or 5- to 14-membered heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl and heteroaryl is substituted with 0, 1, 2, or 3 R2x;
R2c and R2d are each independently H, C1-C3 alkyl, halo, or C1-C6 haloalkyl;
R2e is H, C1-C3 alkyl, halo, C1-C6 haloalkyl, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R1e and R2e can combine with the atoms to which they are attached to form a C5-C6 cycloalkyl, 5- to 10-membered heterocyclyl, C6-C10 aryl, or 5- to 14-membered heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl and heteroaryl is substituted with 0, 1, 2, or 3 R2x;
each R2x is independently C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, or —OH;
L3 is a bond, CR3aR3b, C(═CR3cR3d), C(═O), or ═C(R3e)—;
R3a and R3b are each independently H, C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, —CN, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R3a and R3b can combine with the atom to which they are attached to form a C3-C6 cycloalkyl;
alternatively, R2b and R3b can combine with the atoms to which they are attached to form a C3-C6 cycloalkyl;
R3c and R3d are each independently H, C1-C3 alkyl, halo, or C1-C6 haloalkyl;
R3e is H, C1-C3 alkyl, halo, C1-C6 haloalkyl, C1-C3 cyanoalkyl, or C3-C6 cycloalkyl;
alternatively, R2e and R3e can combine with the atoms to which they are attached to form a C5-C6 cycloalkyl, 5- to 10-membered heterocyclyl, C6-C10 aryl, or 5- to 14-membered heteroaryl;
such that when L2 is ═C(R2e)— then L1 is —C(R1e)═ or L3 is ═C(R3e)—, and when L3 is ═C(R3e)— then L2 is ═C(R2e)—;
RA is phenyl, naphthyl, or 5- to 14-membered heteroaryl, wherein RA is substituted with 0, 1, 2, 3, 4, or 5 RA2;
each RA2 is independently —OH, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C1o alkoxy, C1-C10 hydroxyalkyl, C2-C10 alkoxyalkyl, C1-C6 alkyl-N(RA2a)(RA2b), C1-C10 thioalkyl, halo, C1-C6haloalkyl, —CN, —C(O)RA2a, —C(O)ORA2a, —C(O)N(RA2a)(RA2b), —N(RA2a)C(O)(RA2b), —OC(O)N(RA2a)(RA2b), —N(RA2a)C(O)(ORA2b), oxo, —ORA2a, —SRA2a, —S(O)2RA2a, —S(O)2ORA2a, —N(RA2a)(RA2b), —(C0-C3 alkyl)-SF5, C3-C8 cycloalkyl, —(C1-C6 alkyl)-(C3-C8 cycloalkyl), 3- to 14-membered heterocyclyl, —(C1-C6 alkyl)-(3- to 14-membered heterocyclyl), C6-C14 aryl, —(C1-C6 alkyl)-(C6-C14 aryl), 5- to 14-membered heteroaryl, or —(C1-C6 alkyl)-(5- to 14-membered heteroaryl), wherein each alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, and haloalkyl is substituted with 0, 1, 2, or 3 RA3, and wherein each cycloalkyl, alkyl-cycloalkyl, heterocyclyl, alkyl-heterocyclyl, aryl, alkyl-aryl, heteroaryl, and alkyl-heteroaryl is substituted with 0, 1, 2, or 3 RA4;
each RA2a and RA2b is independently H, C1-C10 alkyl, C1-C6 haloalkyl, or C3-C8 cycloalkyl;
each RA3 is independently halo, —CN, —ORA3a, —SRA3a, —N(RA3a)(RA3b), C3-C8 cycloalkyl, or 5- to 14-membered heteroaryl;
each RA3a and RA3b is independently H, C1-C10 alkyl, C1-C6 haloalkyl, or C3-C8 cycloalkyl;
each RA4 is independently C1-C6 alkoxy, C1-C6 hydroxyalkyl, C2-C6 alkoxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 thiohaloalkyl, C3-C8 cycloalkyl, —(C1-C6 alkyl)-(C6-C10 aryl), halo, —CN, —OH, or —N(RA4a)(RA4b);
each RA4a and RA4b is independently H or C1-C6 alkyl;
alternatively, two RA2 can combine to form a C3-C10 cycloalkyl, C6-C1o aryl, a 3- to 10-membered heterocyclyl, or 5- to 14-membered heteroaryl on two adjacent atoms on RA, wherein each cycloalkyl, aryl, heterocyclyl, and heteroaryl is substituted with 0, 1, 2, or 3 RA5;
each RA5 is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, halo, C1-C6 haloalkyl, —CN, or C3-C8 cycloalkyl;
XB1 is C(RB1)(RB1), O, S or Si(RB1)(RB1);
each XB2 and XB3 is independently C(RB1)(RB);
each RB1 is independently hydrogen, halo, —CN, —OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 cyanoalkyl, C3-C8 cycloalkyl, C6-C14 aryl, or 5- to 14-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C14 aryl or 5- to 14-membered heteroaryl are substituted with 0, 1, 2, or 3 RB3;
alternatively, two RB1 attached to two different atoms can combine to form a C3-C10 cycloalkyl or 4- to 10-membered heterocyclyl, wherein the cycloalkyl and heterocyclyl are substituted with 0, 1, 2, or 3 RB3;
alternatively, two RB1 attached to the same atom can combine to form a C3-C10 cycloalkyl or 4- to 10-membered heterocyclyl, wherein the cycloalkyl and heterocyclyl are substituted with 0, 1, 2, or 3 RB3;
each y and z is independently 1, 2, 3, or 4;
RB2 is H or C1-C6 alkyl;
alternatively, RB2 can combine with RB1 on an adjacent atom to form a C3-C10 cycloalkyl or 4- to 10-membered heterocyclyl, wherein the cycloalkyl and heterocyclyl are substituted with 0, 1, 2, or 3 RB3;
each RB3 is independently C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkoxyalkyl, halo, C1-C6 haloalkyl, C1-C6 haloalkoxy, oxo, —OH, —CN, or C3-C10 cycloalkyl;
RD is halo;
wherein, unless otherwise indicated, each heterocyclyl has 1, 2, 3, or 4 heteroatoms selected from N, O, S, and Si; and
each heteroaryl has 1, 2, 3, or 4 heteroatoms selected from N, O, and S.

### Claim 2 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, having the structure of Formula (Ia):
wherein:
X is N;
L3 is a bond; and
RD is F.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:
L1 is CR1aR1b; and
L2 is CHR2b, wherein R2b is H.

### Claim at position 5

-9. (canceled)

### Claim 10 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein
L1 is —C(R1e)═; and
L2 is ═C(R2e)—.

### Claim at position 7

-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
RA is phenyl substituted with 3 RA2, or
RA is napthyl substituted with 0, 1, 2, 3, 4, or 5 RA2.

### Claim at position 9

-23. (canceled)

### Claim 24 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein RA is

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Z1 is —CH2—.

### Claim 27 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein
ring C2 is 6- to 14-membered heterocyclyl having at least one ring nitrogen, wherein the heterocyclyl has 1, 2, or 3 additional heteroatoms selected from N, O, and S;
each RC2 is independently C1-C6 alkyl, halo, or —OH; and
n is 0, 1, or 2.

### Claim at position 14

-30. (canceled)

### Claim 31 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Z2 is C1-C3 alkyl, C1-C3 alkyl substituted with 1 or 2 halo, C2-C3 alkynyl, —O—C1-C3 alkyl, —O—C2-C3 alkynyl, —O—, or a bond.

### Claim at position 16

-34. (canceled)

### Claim 35 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein
ring C3 is C3-C8 cycloalkyl, 4- to 16-membered heterocyclyl, 5- to 10-membered heteroaryl, or absent, wherein the heterocyclyl and heteroaryl have 1, 2, 3, or 4 heteroatoms selected from N, O, and S;
each RC3 is independently C1-C6 alkyl or halo; and
p is 0, 1, or 2.

### Claim at position 18

-39. (canceled)

### Claim 40 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Z5 is a bond.

### Claim 41 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein
ring C4 is 5 to 14-membered heterocyclyl, C6-C10 aryl or 5- to 10-membered heteroaryl, wherein the heterocyclyl and the heteroaryl each has 1, 2, 3, or 4 heteroatoms selected from N, O, and S;
each RC4 is independently C1-C6 alkyl, halo, oxo, or C3-C6 cycloalkyl; and
q is 0, 1, 2, or 3.

### Claim at position 21

-44. (canceled)

### Claim 45 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Z3 is a bond.

### Claim at position 23

-47. (canceled)

### Claim 48 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:
X is N;
L1 is CR1aR1b or —C(R1e)═;
R1a and R1b are each independently H, C1-C3 alkyl, or halo;
R1e is H or C1-C3 alkyl;
L2 is CHR2b or ═C(R2e)—;
R2b is H, C1-C3 alkyl, or halo;
R2e is H or C1-C3 alkyl;
L3 is a bond;
RA is phenyl or naphthyl, wherein RA is substituted with 0, 1, 2, or 3 RA2;
each RA2 is independently —OH, C1-C10 alkyl, C2-C6 alkynyl, C1-C10 alkoxy, halo, —N(RA2a)(RA2b), wherein each alkyl, alkynyl, and alkoxy is substituted with 0, 1, 2, or 3 RA3;
each RA2a and RA2b is independently H or C1-C10 alkyl;
each RA3 is independently halo;
alternatively, two RA2 can combine to form a C3-C10 cycloalkyl or C6-C10 aryl on two adjacent atoms on RA, wherein each cycloalkyl and aryl is substituted with 0, 1, 2, or 3 RA5;
each RA5 is independently H, C1-C10 alkyl, C2-C10 alkynyl, halo, C1-C6 haloalkyl, or C3-C8 cycloalkyl;
RD is F;
Z1 is —CH2—;
ring C2 is 6- to 14-membered heterocyclyl having at least one ring nitrogen, wherein the heterocyclyl has 1, 2, or 3 additional heteroatoms selected from N, O, and S;
each RC2 is independently C1-C6 alkyl, halo, or —OH;
n is 0, 1, or 2;
Z2 is C1-C3 alkyl, C1-C3 alkyl substituted with 1 or 2 halo, C2-C3 alkynyl, —O—C1-C3 alkyl, —O—C2-C3 alkynyl, —O—, or a bond;
ring C3 is C3-C8 cycloalkyl, 4- to 16-membered heterocyclyl, 5- to 10-membered heteroaryl, or absent, wherein the heterocyclyl and heteroaryl have 1, 2, 3, or 4 heteroatoms selected from N, O, and S;
each RC3 is independently C1-C6 alkyl or halo;
p is 0, 1, or 2;
Z5 is CH2 or a bond;
ring C4 is 5 to 14-membered heterocyclyl, C6-C10 aryl or 5- to 10-membered heteroaryl, wherein the heterocyclyl and the heteroaryl each has 1, 2, 3, or 4 heteroatoms selected from N, O, and S;
each RC4 is independently C1-C6 alkyl, halo, oxo, or C3-C6 cycloalkyl; and
q is 0, 1, 2, or 3;
Z3 is a bond; and
Z4 is —CH— or N.

### Claim 49 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein
Z2 is CH2, CH(CH3), C(CH3)2, —CH2CH2—, —CH2CH2CH2—, CHF, CF2,
—C≡C—, —OCH2—, —CH2O—, —OCH2—C≡C—, —O—, or a bond;
ring C3 is absent or is:
or absent;
Z5 is absent or CH2;
ring C4 is
and
Z4 is —CH— or N.

### Claim 50 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein the moiety
is

### Claim 51 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein the compound has the structure:

### Claim 52 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein the compound has the structure:

### Claim 53 (depends on 1)

The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein the compound has the structure:

### Claim at position 30

-58. (canceled)

### Claim 59 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim at position 32

60-102. (canceled)
